TheraCryf (LSE:TCF) Asset Impairment Charge : £0.00 Mil (TTM As of Sep. 2024)

View and export this data going back to 2015. Start your Free Trial

What is TheraCryf Asset Impairment Charge?

TheraCryf's Asset Impairment Charge for the six months ended in Sep. 2024 was £0.00 Mil. Its Asset Impairment Charge for the trailing twelve months (TTM) ended in Sep. 2024 was £0.00 Mil.

TheraCryf Asset Impairment Charge Historical Data

The historical data trend for TheraCryf's Asset Impairment Charge can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

TheraCryf Asset Impairment Charge Chart

TheraCryf Annual Data

Trend

Mar15

Mar16

Mar17

Mar18

Mar19

Mar20

Mar21

Mar22

Mar23

Mar24

Asset Impairment Charge

Get a 7-Day Free Trial

TheraCryf Semi-Annual Data
	Mar15	Sep15	Mar16	Sep16	Mar17	Sep17	Mar18	Sep18	Mar19	Sep19	Mar20	Sep20	Mar21	Sep21	Mar22	Sep22	Mar23	Sep23	Mar24	Sep24
Asset Impairment Charge	Get a 7-Day Free Trial															-	-	-	-	-

TheraCryf Asset Impairment Charge Calculation

Asset Impairment Charge is the charge against earnings resulting from the aggregate write down of all assets from their carrying value to their fair value.

Asset Impairment Charge for the trailing twelve months (TTM) ended in Sep. 2024 adds up the semi-annually data reported by the company within the most recent 12 months, which was £0.00 Mil.

TheraCryf Asset Impairment Charge Related Terms

Thank you for viewing the detailed overview of TheraCryf's Asset Impairment Charge provided by GuruFocus.com. Please click on the following links to see related term pages.

TheraCryf Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » TheraCryf PLC (LSE:TCF) » Definitions » Asset Impairment Charge

Comparable Companies

Traded in Other Exchanges

N/A

Address

Congleton Road, Alderley Park, Nether Alderley, Cheshire, GBR, SK10 4TG

Website

https://www.evgen.com

TheraCryf PLC is a clinical-stage biotechnology company focused on profitable segments in oncology and neuropsychiatry. The company's lead clinical asset, SFX-01 is a patented form of delivering sulforaphane, which could be used in the treatment of a number of cancers, neurodevelopmental disorders, and other diseases.